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A B S T R A C T
The aim of this study was to improve the in vitro dissolution rate and oral bioavailability of
oleanolic acid (OA), a water insoluble drug belonging to BCS class IV. Hot melt extrusion
(HME) was applied to develop OA amorphous solid dispersions. The characterizations of
the optimal formulation were performed by differential scanning calorimetry, X-ray
powder diffraction, Fourier transform infrared spectroscopy and in vitro dissolution test.
The in vivo pharmacokinetic study was conducted in rats. As a result, OA solid dispersion
based on PVP VA 64 (OA-PVP) was successfully prepared. In the dissolution medium
containing 0.3% SDS, OA-PVP dramatically increased the releasing rate of OA compared
with the physical mixture (PM-PVP) and commercial tablet. Furthermore, OA-PVP exhib-
ited higher AUC (P < 0.05) and Cmax (P < 0.05) than PM-PVP and commercial tablet. The
superior dissolution property and bioavailability of OA-PVP mainly attributed to the
amorphous state of OA in PVP VA64 and the well dispersion caused by thermal melting
and shearing. Overall, hot melt extrusion was an efficient strategy to enhance the
dissolution rate and oral bioavailability of OA.
© 2017 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This









Oleanolic acid (OA) is a bioactive pentacyclic triterpenoid
compound widely existing in Asian herbs [1]. Its clinical
pharmacology activities mainly include hepatoprotective, anti-
inflammatory, antibacterial and antiulcer effect [2]. As a
natural origin drug, OA owes a good application prospect due
to its low toxicity. However, it exhibits low bioavailability
after oral administration on account of the poor aqueous
solubility (<1 μg/ml) [3] and poor permeability (Papp = 1.1–
1.3 × 10−6 cm/sec in the apical-to-basolateral direction at 10
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and 20 μM) [4]. Jeong et al. reported that the absolute oral
bioavailability of OA was 0.7% for oral doses of 25 and
50 mg/kg. The very low oral bioavailability of OA could be
due to a poor absorption and extensive metabolic clearance
[4].
Many attempts were made to improve the solubility of OA,
such as solid lipid nanoparticles [5], nanosuspensions [6–8],
β-cyclodextrin inclusion compounds [9], self-nanoemulsified
formulations [10], phospholipid complexes [11] and solid dis-
persions [12,13]. However, the complicated unavailable scale-
up process and the presence of organic solvents limit their
application in the production process.
In recent years, hot melt extrusion (HME) has gained great
interest in pharmaceutical field due to many advantages,
such as scalable continuous processing, solvent-free and
environmentally friendly [14,15]. In the HME process, drug
and polymers are mixed thoroughly under the controlled
temperature and pumped with a rotating screw through a
die plate, yielding solid dispersions. To obtain a desirable
product, the extrusion temperature is typically set 30–60 °C
higher than theTg (glass transition temperature) or Tm (melting
temperature) of polymers, which will soften the mixture and
provide a good flowability [16–18]. In addition, polymers play
an important role in stabilizing the metastable solid, inhibit-
ing crystallization [19] and maintaining supersaturation during
dissolution [20,21]. Several hydrophilic polymers are devel-
oped for the HME process, for example, polyvinyl
caprolactampolyvinyl acetate-polyethylene glycol graft copo-
lymer (Soluplus®), polyvinylpyrrolidone-vinyl acetate copolymer
(PVP VA64), polyethylene glycol (PEG), Eudragit® EPO, and
hypromellose acetate succinate (HPMCAS). However, the mis-
cibility of drugmolecular and polymers needs to be investigated.
In the present study, we developed a HME method to im-
proving the dissolution and oral bioavailability of OA by
preparation of solid dispersions. Hydrophilic polymers, drug-
to-carrier ratio and extrusion temperature were optimized.
Thermal gravimetric analysis was used to detect weight loss
due to degradation of OA. Differential scanning calorimetry
(DSC), X-ray powder diffraction (XRPD), Fourier transform in-
frared (FT-IR) spectroscopy and in vitro dissolution were carried
out to characterize the optimal formulation. Furthermore, the
pharmacokinetic study was evaluated in rats.
2. Materials and methods
2.1. Materials
OAwas purchased fromWuhan Dahua Pharmaceutical Co., Ltd.
(Wuhan, Hubei). Soluplus® and PVPVA64 were purchased from
BASF Co., Ltd. (Shanghai, China). PEG 6000 was obtained from
Beijing Fengli Jingqiu Pharmaceutical Co., Ltd. (Beijing, China).
Sodium dodecyl sulfate (SDS) was purchased fromTianjin Bodi
Chemical Holding Co., Ltd. (Tianjin, China). H3PO4 was ob-
tained fromTianjin Kemiou Chemical Reagent Co., Ltd. (Tianjin,
China). Glycyrrhetinic acid was obtained from China’s food and
drug administration. Methanol, Methyl tert-Butyl Ether of HPLC
grade was purchased from Thermo Fisher Scientific (Shang-
hai, China). Ammonium acetate (HPLC grade) was purchased
from Dikma Technology Inc. (Beijing, China).
2.2. Preparation of hot-melt extrudates
OA was mixed with the hydrophilic carriers at a ratio of 1:10
(drug: carrier, w/w) to obtain the physical mixtures (PMs) by
the method of increment by equal quantity.Then the PMs were
extruded by a co-rotating twin-screw extruder (AK-26; Coperion
Keya Co., Najing, China) at temperature of 160 °C. The screw
rate was set at 20 rpm.The extrudates were collected from the
die and cooled at ambient temperature. A universal high-
speed smashingmachine (FW400A, Zhongxingweiye instrument
Co., Ltd, Beijing, China) was used to crushing the banded product
into powder. After passing through an 80-mesh screen, the ob-
tained solid dispersions powder was stored in dry dark
conditions for further in vitro dissolution test and in vivo phar-
macokinetic study.
2.3. Characterization of solid dispersions
2.3.1. Thermal analysis
The thermal stability of OA was determined on a thermal gravi-
metric analyzer (TGA-50, Shimadzu, Japan). Samples were
heated from 30 to 400 °C at a rate of 10 °C/min with an empty
aluminum pan as the reference. Nitrogen was used as the purge
gas at a flow rate of 40 ml/min. Plots of weight versus tem-
perature were recorded.
Differential scanning calorimetry (DSC) thermograms of the
samples were conducted using a DSC1 STAR® system (Mettler
Tolelo, Switzerland) equipped with a cooling system. Samples
(3–5 mg) were weighted accurately and loaded in the alumi-
num pans. The DSC cell was purged by using nitrogen gas at
flow rate of 40 ml/min. A heating rate of 20 °C/min was used
to scan from 40 to 330 °C. All results were analyzed using the
STARe software.
2.3.2. XRPD
XRPD analysis was performed on a D\Max-2400 X-Ray powder
diffractometer (Rigaku, Japan) at ambient temperature. Mono-
chromatic Cu-Kα radiation (λ = 1.5406 Å) was used in the 2θ
angle range from 3° to 50° with a step width of 0.05°.The voltage
and current of the equipment were 30 mA and 40 kV.
2.3.3. FT-IR
FT-IR spectra of samples were measured using an EQUINOX55
Fourier infrared spectrometer (Bruker, Germany) instrument.
The samples were mixed with KBr using a mortar and pestle,
and then compressed to prepare a disk. The spectra were re-
corded over a wavenumber range of 4000 cm−1 to 400 cm−1, with
a resolution of 4 cm−1.
2.3.4. In vitro dissolution testing
The in vitro drug release from samples was tested according
method 2 as described in the Chinese Pharmacopeia 2010 using
a dissolution tester (ZRS-8G, Tianda Tianfa Science and Tech-
nology Ltd.,Tianjin, China). Samples equivalent to 20 mg of OA
were loaded into 00 capsule shells and sunk into 900 ml of de-
ionized water containing 0.3% (w/v) SDS at a temperature of
37 ± 0.2 °C.The paddle rotation speed was set to 100 rpm. 5 ml
of samples were withdrawn at predetermined time intervals
5, 10, 20, 30, 45, 60 and 120 min and filtered through a 0.45 μm
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microfiltration membrane.The same volume of fresh medium
was replaced at each time point. Then, 20 μl of each subse-
quent filtrate was injected into HPLC for analysis. All
experiments were performed in triplicate.
A HITACHI HPLC system equipment equipped a UV Detec-
tor 5430 and a pump 5110 (HITACHI Ltd, Japan) was used to
determine the concentrations of OA.The separation of OA was
conducted on a Cosmosil C18 (150 μm × 4.6 μm, 5 μm) column.
The mobile phase was methanol and purified water contain-
ing 0.1% phosphoric acid (90:10, v/v) with a flow rate of 1 ml/
min.The column temperature was set at 25 °C and the detector
was operated at 210 nm.
2.4. In vivo pharmacokinetic study
The pharmacokinetic study was performed in male Sprague
Dawley (SD) rats (250 ± 5 g).The experiment was conducted ac-
cording to the “Guidelines for the Care and Use of Laboratory
Animals” and approved by the Animal Ethics Committee of
Shenyang Pharmaceutical University (Shenyang, China). SD rats
(n = 15) were randomly divided into three groups, and fasted
overnight before dosing and fed 6 h after dosing. The opti-
mized OA solid dispersion, physical mixture of OA and carrier
(1:10,w/w) and commercial tablet were suspended in deionizer
water and orally administered to the animals at a dosage of
50 mg/kg. Blood samples (0.2 ml) were collected from the orbit
before dosing and at 0.08, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and
24 h after dosing. After centrifuged at 13,000 rpm for 10 min,
the plasma samples were obtained and stored at −20 °C until
analysis.
2.5. Sample preparation
Frozen plasma samples were thawed at room temperature, and
50 μl of each sample was transformed into a 10 ml polypro-
pylene tube. A liquid–liquid extraction procedure was applied
to extract the analyte. 50 μl internal standard (IS) solution con-
taining glycyrrhetinic acid 1 μg/ml and 50 μl methanol-water
(85:15, v/v) was added to the samples and vortexed for 1 min.
Then, 3 ml of methyl tert-butyl ether was added and vortexed
for another 3 min. After centrifuged at 3500 rpm for 10 min,
the supernatant was transformed and dried at 37 °C under a
soft nitrogen gas flow.The residue was reconstituted with 100 μl
methanol-water (85:15, v/v) and 5 μl was injected into the
Acquity UPLC™ system (Waters Co., Ltd., Milford, Ma, USA).
2.6. UPLC-MS/MS analysis
OA was separated using a Phenomenex XB-C18 (50 × 2.1 mm,
2.6 μm) column. The mobile phase consisted of menthol and
water with 10 Mm ammonium acetate (85:15, v/v).The flow rate
was 0.2 ml/min at the first twominutes, and changed to 0.25ml/
min within 0.01 min. After maintaining there from 2.01 to
3.99 min, the flow rate returned to 0.2 ml/min in 0.01 min.The
column temperature was maintained at 30 °C.
Detection of OA was performed in negative ion mode with
an ESI source. Selective ion reaction (SIR) was applied tomonitor
the transitions of m/z 455.5 and m/z 469.5 for OA and IS, re-
spectively, with a scan time of 0.2 sec.The capillary voltage was
set at 2.54 kV. The cone voltage was 55 and 35 V for OA and
IS, respectively. The ion source temperature and desolvation
temperature was set at 120 and 500 °C. The method showed
good linearity over the concentration range of 10–1000 ng/ml
for OA.The pharmacokinetic parameters were calculated using
DAS 2.1.1 software and the values were expressed asmean ± S.D.
2.7. Statistical analysis
Statistical analysis was carried out using Student’s t-test by
IBM SPSS statistics 21.0 software. Differences were consid-
ered statistically significant if the P value was less than 0.05
(P < 0.05).
3. Results and discussion
3.1. Preparation of OA solid dispersions
Hot melt extrusion was applied to prepare OA amorphous solid
dispersions. However, amorphous drug substances are physi-
cally unstable on account of their high energy state and tend
to recrystallize. Therefore, in the present study, three polymer
carriers Soluplus®, PVPVA64 and PEG 6000 were used to prepare
OA solid dispersions (OA-SOL, OA-PVP and OA-PEG) at a drug-
to-carrier ratio of 1:10 (w/w). The extrusion temperature was
set at 160 °C for OA-SOL and OA-PVP, and 80 °C for OA-PEG. From
Fig. 1A, the cumulative released quantities were 40% and 80%
for OA-PEG and OA-SOL after 2 h, while over 90% of OA was
dissolved for OA-PVP within 10 min.The results indicated that
PVPVA64 obviously enhanced the dissolution of OA, which was
chosen as the efficient carrier.
Subsequently, the effect of drug-to-carrier ratio ranging from
1:3 to 1:15 on dissolution of OA solid dispersion was investi-
gated.As shown in Fig. 1B, the extrudates with lower percentage
of PVPVA64 demonstrated lower dissolution.This may be due
to the low solubility of the OA in the dissolution medium.
However, at a drug-to-carrier ratio of 1:10, over 90% of the drug
released from the hydrophilic matrix within the first 10 min.
No further increase was obtained with extra amount of PVP
VA64 (1:15), thus the optimal ratio of drug to PVPVA64 was 1:10.
Hot melt extrusion technology is a thermal processing tech-
nique, which increases the risk of thermal degradation of drugs.
In addition, the extrusion temperature greatly influences the
miscibility of drug and carrier and the rheological properties
of a molten formulation. Thermo gravimetric analysis (Fig. 2)
showed that OA was thermally stable and no weight lost before
250 °C. Meanwhile, in the preliminary experiment, the ex-
truder barrels stopped below 140 °C due to high torque, and
the extrudates became more molten and dark yellow above
170 °C. Hence, the temperature range was investigated from
140 to 170 °C. As can be seen in Fig. 1C, an increasing disso-
lution was obtained with the increasing temperature. This is
because, higher extrusion temperature lowered the melt vis-
cosity, which made the material flow faster inside the extruder
and dispersed homogeneously in the carrier. The extrudates
from 160 °C and 170 °C showed similar dissolution behavior,
nevertheless, the degradation of OA at 170 °C was higher than
at 160 °C (1.43% vs 0.22%). Therefore, the extrusion tempera-
ture was controlled at 160 °C.
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3.2. Thermal analysis
The DSC curves of OA, PVP VA64, physical mixture and OA-
PVP were presented in Fig. 3. The pure OA exhibited a first
endothermic peak at 130 °C, which was probably due to the
loss of methanol from the OA methanol crystallization solvate
[3,22]. An exothermic peak at 190 °C indicated a transforma-
tion of OA frommetastable state to crystalline state, which was
also observed by Sun et al. [5]. The sharp endotherm peak at
310 °C was corresponding to the melting point of OA.The physi-
cal mixture of OA and PVP VA64 also showed the weakened
endothermic peak of OA. However, the disappearance of en-
dothermic peak in OA-PVP indicated that OA existed as
amorphous state.
3.3. XRPD
XRPD was used to confirm the crystal form of OA in OA-PVP.
The XRPD patterns of OA, PVPVA64, physical mixture and OA-
PVP were shown in Fig. 4. The pure OA exhibited strong sharp
peaks at 8.43, 12.99, 13.68, 15.36, 19.56 and 20.97°, indicating
the crystalline state of the drug. However, in the pattern of OA-
PVP, no distinct diffraction peaks were observed, indicating that
the drug was in an amorphous state.The results of XRPD were
in agreement with that of DSC.
3.4. FT-IR
The interaction of OA and PVPVA64 was detected by FT-IR spec-
troscopy and the results were demonstrated in Fig. 5. The
characteristic absorption peaks at 1697.6 and 3432.4 cm−1 were
the stretch vibration of —C=O and —OH in OA. PVP VA64 ex-
hibited peaks of —OH stretch vibration (3463.5 cm−1), —C=O
stretch vibration (1738.8 cm−1) in ester group and—C=O stretch
Fig. 1 – Dissolution profiles of: A. OA solid dispersion with Soluplus®, PVP VA64 and PEG 6000 as carriers; B. OA solid
dispersion with PVP VA64 as carrier at different drug-to-carrier ratio of 1:3, 1:5, 1:7, 1:10 and 1:15; C. OA-PVP extruded at
extrusion temperature of 140 °C, 150 °C, 160 °C and 170 °C; D. OA-PVP, PM-PVP and commercial tablet.
Fig. 2 – TGA thermogram of OA.
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vibration (1678.7 cm−1) in amide group. The FT-IR spectra of
physical mixture showed a summation of drug and PVPVA64.
However, after the hot melt extrusion process, the peak of
—C=O of OA shifted to 1678.8 cm−1, and the peak of —OH
stretch vibration of PVP VA64 shifted to 3457.8 cm−1. This was
indicative of hydrogen bonds interactions between OA and PVP
VA64.
3.5. In vitro dissolution testing
The in vitro dissolution profiles of commercial tablet, physical
mixture and OA-PVP solid dispersion were shown in Fig. 1D.
A dissolution medium containing 0.3% (w/v) SDS was used to
provide sink condition. From the results, the solid dispersion
OA-PVP dramatically improved the dissolution rate of OA, and
about 90% of the drug was released within 10 min. The im-
provement of OA-PVP extrudate was attributed to the
transformation of crystalline drug into amorphous state that
no energy was required to break up the crystal lattice of OA
during the dissolution process [23]. Furthermore, the solubil-
ity and wettability of OA can be improved by PVP VA64 due to
its excellent solubilizing property [24].The dissolution of physi-
cal mixture (the accumulative dissolution was about 45%
after 2 h) showed slightly enhancement compared with
Fig. 3 – DSC thermograms of A. OA, B. PM-PVP, C. PVP VA64, and D. OA-PVP.
Fig. 4 – XRPD patterns of A. OA, B. PM-PVP, C. PVP VA64,
and D. OA-PVP.
Fig. 5 – FT-IR spectrogram of A. OA, B. PM-PVP, C. PVP VA64,
and D. OA-PVP.
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commercial tablet (the accumulative dissolution was about 37%
after 2 h). This may be for the reason that the solubilization
of PVPVA64 created a hydrodynamic layer surrounding the drug
particles and inhibited the recrystallization of the drug in
aqueous environment [24].
3.6. In vivo pharmacokinetic study
Oral absorption of OA from OA-PVP, PM-PVP and commercial
tablet was evaluated in rats at a dosage of 50 mg/kg. The
mean plasma concentration-time profiles were shown in
Fig. 6 and the main pharmacokinetic parameters were sum-
marized in Table 1. As shown, the AUC0–24 (1840 ± 381.8 ng·h/
ml) of OA-PVP was 3.0-fold and 2.4-fold higher than that of
PM-PVP and commercial tablet (P < 0.05), while the Cmax
(498.7 ± 120.8 ng/ml) of OA-PVP was found to be 3.7-fold and
5.6-fold higher, respectively (P < 0.05). The results indicated
that OA-PVP exhibited superior oral bioavailability, which
may be attributed to the enhanced dissolution after prepara-
tion of solid dispersion with PVP VA64. The Cmax of PM-PVP
was slightly higher than the commercial tablet. This may be
due to solubilization of PVP VA64 surrounding the OA crystal-
line particles improved its dissolution in the gastrointestinal
tract. However, no significant difference was observed between
these two formulations. Thus, solid dispersion prepared by
hot melt extrusion method was a potential strategy for
improving the oral bioavailability of OA.
4. Conclusions
OA amorphous solid dispersion based on PVP VA64
was developed using hot melt extrusion method. The
drug-to-carrier ratios and extrusion temperatures were opti-
mized according to the dissolution of the extrudates.The crystal
form of the optimal formulation, OA-PVP, was characterized
by DSC and XRPD, which indicated that OA existed in amor-
phous state and dispersed homogenously in PVP VA64. FT-IR
spectra revealed the formation of hydrogen bond between OA
and the polymer molecules. The in vitro and in vivo evalua-
tion showed a remarkable improvement of OA-PVP compared
with PM-PVP and commercial tablet. These results indicated
that the amorphization of OA by HME process was a poten-
tial method to enhancing its oral absorption.
Fig. 6 – Plasma concentration-time curves of OA after oral administration of OA-PVP, PM-PVP, and commercial tablet to SD
rats (data are mean ± S.D., n = 5).
Table 1 – Pharmacokinetic parameters of OA after oral administration of OA-PVP, PM-PVP, and commercial tablet to SD
rats (data are mean ± S.D., n = 5).
Pharmacokinetic parameters OA-PVP PM-PVP Commercial tablet
AUC0–24 (ng·h/mL) 1840 ± 381.8* 615.1 ± 115.5 761.8 ± 272.2
AUC0–∞ (ng·h/mL) 2039.5 ± 483.4* 696.8 ± 151.6 875.08 ± 292.1
Cmax (ng/mL) 498.7 ± 120.8* 134.4 ± 47.4 89.1 ± 33.1
Tmax (h) 1.1 ± 0.5 1.1 ± 1.0 1.8 ± 1.6
F (%) 241.53 80.74 100
Note: P < 0.05 (*) versus the commercial tablet as the control.
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